PMA device
Eversense® Continuous Glucose Monitoring System
Senseonics, Incorporated · Continuous Glucose Monitor, Implanted, Adjunctive Use (QCD, Class III) · First FDA decision Jun 21, 2018, newest Mar 19, 2026Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
12
Naming "Eversense"
MAUDE reports
8,174
Brand "Eversense", since 2015
PubMed studies
35
Mentioning "Eversense"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Eversense® Continuous Glucose Monitoring System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- Eversense® Continuous Glucose Monitoring SystemPMA supplement
P160048-S031 · Decided Mar 19, 2026 · 24 days after receipt · Normal 180 Day Track No User Fee
Device type: Continuous glucose monitor, implanted, adjunctive use (QCD) · Laboratory Medicine & Pathology
- Eversense Continuous Glucose Monitoring SystemPMA supplement
P160048-S007 · Decided Jan 15, 2019 · 48 days after receipt · Normal 180 Day Track No User Fee
Device type: Continuous glucose monitor, implanted, adjunctive use (QCD) · Laboratory Medicine & Pathology
- Eversense Continuous Glucose Monitoring System (CGMS-Entire System), Eversense Sensor , Eversense Insertion Tools, EversPMA supplement
P160048-S003 · Decided Feb 1, 2019 · 158 days after receipt · Normal 180 Day Track No User Fee
Device type: Continuous glucose monitor, implanted, adjunctive use (QCD) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38662CGS Administrators, LLCUpdated Sep 29, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38623Wellpoint FederalUpdated Jul 14, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38686WPS Insurance CorporationUpdated Jun 18, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38657Noridian Healthcare Solutions, LLCUpdated Oct 14, 2025
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38743Palmetto GBAUpdated Jul 19, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38664First Coast Service Options, Inc.Updated Jun 21, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38617Novitas Solutions, Inc.Updated Jun 21, 2024
- Home Blood Glucose MonitorsNational analysisReview closedCAG-00161NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Eversense", any status and sponsor, newest update first.
Senseonics, Inc.Public (SENS)
NCT07386340 · 80 participants (planned) · Start Dec 29, 2025 · Primary completion Dec 2027
Device: Continuous Glucose Monitoring System · For: Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Sites: Escondido, California
- ROME GS System StudyRecruiting
Senseonics, Inc.Public (SENS)
NCT07518004 · 60 participants (planned) · Start Feb 12, 2026 · Primary completion Aug 2028
Device: Continuous Glucose Monitoring System · For: Diabetes; Diabetes Melletus, Type 1; Diabetes Mellitus, Type 2
Sites: Escondido, California; Walnut Creek, California; San Antonio, Texas · 4 sites in all
- Eversense® Non-adjunctive Use Post Approval StudyActive, not recruiting
Senseonics, Inc.Public (SENS)
NCT04836546 · 925 participants (planned) · Start Apr 13, 2021 · Primary completion Mar 31, 2026
Device: Blood glucose meter; Eversense CGM System · For: Diabetes
Sites: Los Angeles, California; Englewood, Colorado; Hamden, Connecticut · 23 sites in all
9 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Eversense", and for the whole product code for context.
This brand
8,174 reports: 5,069 malfunction, 3,085 injury, 1 death
Whole product code QCD
1,514 reports: 566 malfunction, 948 injury, 0 death
Newest reports for this brand
- Eversense SensorInjury
3009862700-2026-03620 · Received Oct 30, 2026 · Event dated Sep 30, 2026
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hyperglycemia
- Eversense SensorInjury
3009862700-2026-03623 · Received Oct 30, 2026 · Event dated Sep 30, 2026
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA)
Device problem as coded: Difficult to Remove
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- Eversense SensorInjury
3009862700-2026-03609 · Received Oct 30, 2026 · Event dated Sep 8, 2026
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Medical device site infection
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0251-2020 · Started Sep 18, 2019
Reason given: Eversense Sensors have prematurely stopped functioning due to inadequate hydration of the sensor s glucose-sensing surface
Cause as FDA categorized it: Process control · Device type: Sensor, Glucose, Implanted, Non-Adjunctive Use (QHJ)
Published research
The most relevant PubMed records for "Eversense"[tiab]. The summary above synthesizes these.
- Diboronate Fluorophore for the Measurement of l-Glucose and Other Carbohydrates and Its Interaction with Albumin.
Solomos K, Tarus V, Kotek V, et al. · ACS Omega · 2022
- Real-World Data from the First U.S. Commercial Users of an Implantable Continuous Glucose Sensor.
Sanchez P, Ghosh-Dastidar S, Tweden KS, et al. · Diabetes Technol Ther · 2019Research Support, Non-U.S. Gov't
- Longitudinal Analysis of Real-World Performance of an Implantable Continuous Glucose Sensor over Multiple Sensor Insertion and Removal Cycles.
Tweden KS, Deiss D, Rastogi R, et al. · Diabetes Technol Ther · 2020
- Review of the Long-Term Implantable Senseonics Continuous Glucose Monitoring System and Other Continuous Glucose Monitoring Systems.
Joseph JI · J Diabetes Sci Technol · 2021Research Support, Non-U.S. Gov't
- Clinical Use of a 180-Day Implantable Glucose Monitoring System in Dogs with Diabetes Mellitus: A Case Series.
Tardo AM, Irace C, Del Baldo F, et al. · Animals (Basel) · 2022Case Reports
- A Prospective Multicenter Evaluation of the Accuracy and Safety of an Implanted Continuous Glucose Sensor: The PRECISION Study.
Christiansen MP, Klaff LJ, Bailey TS, et al. · Diabetes Technol Ther · 2019Multicenter Study, Research Support, Non-U.S. Gov't
- Performance of the Eversense versus the Free Style Libre Flash glucose monitor during exercise and normal daily activities in subjects with type 1 diabetes mellitus.
Fokkert M, van Dijk PR, Edens MA, et al. · BMJ Open Diabetes Res Care · 2020Observational Study, Research Support, Non-U.S. Gov't
- A Novel and Easy Method to Locate and Remove First Approved Long-Term Implantable Glucose Sensors.
Akturk HK, Brackett S · Diabetes Technol Ther · 2020Research Support, Non-U.S. Gov't
- Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases.
Almurashi AM, Rodriguez E, Garg SK · J Indian Inst Sci · 2023Review
- A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II.
Christiansen MP, Klaff LJ, Brazg R, et al. · Diabetes Technol Ther · 2018Evaluation Study, Multicenter Study
- Clinical use of a 180-day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes.
Irace C, Cutruzzolà A, Nuzzi A, et al. · Diabetes Obes Metab · 2020Multicenter Study, Observational Study
- Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study.
Bailey TS, Liljenquist DR, Denham DS, et al. · Diabetes Technol Ther · 2025Multicenter Study
Other devices of this type
Also filed under product code QCD.
- Eversense E3 Continuous Glucose Monitoring System (CGM System) - Entire SystemSenseonics, Incorporated · PMA 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.